drugset
Drugs / rVSVΔ-ZEBOV-GP
last change Nov 2015 re-read 3 minutes ago

rVSVΔ-ZEBOV-GP

Vaccine

Developed for
Ebola hemorrhagic fever
Investigated by
Albert Schweitzer Hospital · Clinical Trial Center North · German Center for Infection Research · Institute of Tropical Medicine, University of Tuebingen · KEMRI-Wellcome Trust Collaborative Research Program · Philipps University Marburg
+4 more · University Hospital, Geneva · University Medical Center Hamburg-Eppendorf · Wellcome Trust · World Health Organization

Trials 1

today NCT02283099 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02283099 Nov 2014 → Nov 2015 Ebola hemorrhagic fever University Medical Center Hamburg-Eppendorf Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rVSVΔ-ZEBOV-GP ClinicalTrials.gov intervention name — accepted as the source's own label NCT02283099 ↗
Modality Vaccine “an Ebola Virus Vaccine candidate” NCT02283099 ↗
Route Intramuscular “administered as an i.m. injection.” NCT02283099 ↗